{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Radenkovic S"],"funding":["NINDS NIH HHS"],"pagination":["108530"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12682075"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["142(4)"],"pubmed_abstract":["Phosphoglucomutase-1-congenital disorder of glycosylation (PGM1-CDG) is a rare genetic disorder caused by biallelic variants in the PGM1 gene, leading to the deficiency of the PGM1 enzyme. The most common clinical presentations include muscle involvement, failure to thrive, cleft palate, and cardiac involvement. Abnormal serum N-glycosylation, hypoglycemia, and liver function abnormalities including coagulation abnormalities are the most common laboratory abnormalities. While PGM1-CDG has been extensively studied, little is known about the extent of the coagulation abnormalities in individuals with PGM1-CDG. Unlike most CDG, some symptoms of PGM1-CDG are treatable with D-galactose (D-gal) supplementation, though reliable clinical endpoints are necessary to appropriately evaluate the potent"],"journal":["Molecular genetics and metabolism"],"pubmed_title":["Coagulation abnormalities and vascular complications are common in PGM1-CDG."],"pmcid":["PMC12682075"],"funding_grant_id":["U54 NS115198"],"pubmed_authors":["Bleukx S","Eklund E","Edmondson AC","Mercimek-Andrews S","Radenkovic S","Morava E","Engelhardt N"],"additional_accession":[]},"is_claimable":false,"name":"Coagulation abnormalities and vascular complications are common in PGM1-CDG.","description":"Phosphoglucomutase-1-congenital disorder of glycosylation (PGM1-CDG) is a rare genetic disorder caused by biallelic variants in the PGM1 gene, leading to the deficiency of the PGM1 enzyme. The most common clinical presentations include muscle involvement, failure to thrive, cleft palate, and cardiac involvement. Abnormal serum N-glycosylation, hypoglycemia, and liver function abnormalities including coagulation abnormalities are the most common laboratory abnormalities. While PGM1-CDG has been extensively studied, little is known about the extent of the coagulation abnormalities in individuals with PGM1-CDG. Unlike most CDG, some symptoms of PGM1-CDG are treatable with D-galactose (D-gal) supplementation, though reliable clinical endpoints are necessary to appropriately evaluate the potent","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-05-23T03:25:54.46Z","creation":"2026-05-23T03:13:56.696Z"},"accession":"S-EPMC12682075","cross_references":{"pubmed":["38968673"],"doi":["10.1016/j.ymgme.2024.108530"]}}